Dare Bioscience Inc (DARE)

[Eurotradr]

Daré Bioscience CEO to Participate in Maxim Group’s Infectious Disease Virtual Conference:

SAN DIEGO, April 28, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.(DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will participate in a panel discussion during the Infectious Disease Virtual Conference presented by Maxim Group on May 5, 2020. Ms. Johnson will be a member of the panel discussing non-antibiotic anti-infectives, scheduled from 10:30 a.m. to 12:00 p.m. Eastern Time.

During the panel discussion, Ms. Johnson will share insights from the Company’s DARE-BV1 development program. DARE-BV1, a novel thermosetting bio-adhesive hydrogel formulated with clindamycin phosphate 2%, is an investigational product for the treatment of bacterial vaginosis (BV), one of the most common vaginal infections. The Company plans to initiate a Phase 3 study of DARE-BV1 during 2020, have topline data available by the end of the year and submit a new drug application (NDA) for DARE-BV1 with the FDA during the first half of 2021.

For additional information, please visit https://m-vest.com/insights/blog/Infectious-Disease-Virtual-Conference-2020.